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ABSTRACT
Pharmacological treatment of cancer is mostly limited by drug-toxicity and 
resistance. It has been noticed that new organic ester ligand, O,O’-diethyl-(S,S)-
ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate dihydrochloride (named DE-
EDCP) showed effective cytotoxic capacities against several human and mouse cancer 
cell lines. However, its effects on tumor growth and metastasis are unexplored. The 
aim of present study was to examine the ability of DE-EDCP to inhibit 4T1 murine 
breast cancer growth and progression and to explore possible molecular mechanisms. 
DE-EDCP exhibited significant tumoricidal activity on human and murine breast 
cancer cell lines. Further, marked reduction of murine breast cancer growth and 
progression by DE-EDCP was shown. DE-EDCP exhibits fewer side-effects compared 
to cisplatin as a conventional chemotherapeutic. Results obtained from in vivo and in 
vitro experiments indicate that DE-EDCP induces apoptosis and inhibits proliferation 
of 4T1 cells. DE-EDCP increases percentage of 4T1 cells in late apoptosis, expression 
of pro-apoptotic Bax and caspase-3, while decreases expression of anti-apoptotic 
Bcl-2. DE-EDCP treatment increased the percentage of TUNEL-positive nuclei and 
reduced Ki-67 expression in breast cancer tissue. DE-EDCP decreased expression of 
cyclin D3 and Ki-67, increased expression of cyclin-dependent kinase inhibitors p16, 
p21 and p27 and arrested 4T1 cells in G0/G1 cell cycle phase. Expression of STAT3 
and downstream regulated molecules, NANOG and SOX2, was reduced in 4T1 cells 
after DE-EDCP treatment.
In conclusion, DE-EDCP impairs breast cancer growth and progression by 
triggering cancer cell death and inhibition of cancer cell proliferation. DE-EDCP might 
be of interest in the development of the new anticancer agent.
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INTRODUCTION
Cancer is on its way to become number one killer 
across the world [1]. Platinum-based drugs are one of 
the mostly used anticancer agents [2, 3]. Cisplatin or 
cis-diamminedichloroplatinum(II) is the most widely 
known metal-based anticancer drug, used for treatment 
of a variety of malignancies, including breast cancer [4]. 
However, clinical utility of cisplatin has been often limited 
due to toxicity [5–7] and acquired or intrinsic resistance 
[8–10]. The lack of efficiency caused by these limiting 
factors is the main reason why vigorous attempts are 
committed to develop novel platinum complexes which 
might overcome the shortcomings of cisplatin.
Large number of edda (ethylenediamine-N,N’-
diacetate)-type ligands and their corresponding platinum 
complexes have been successfully synthesized [11, 12] 
and some of them showed significant cytotoxic effects 
[13].
It has been shown that platinum(IV) [14] 
and platinum(II) [15] complexes with cyclohexyl-
functionailized ehylenediamine-N,N’-diacetate-type ligand 
exhibit effective tumoricidal capacities against various 
cancer cell lines. The cytotoxic effects of these platinum 
complexes may be at least partly related to their organic 
ligands (ester derivatives of (S,S)-ethylenediamine-
N,N′-di-2-(3-cyclohexyl)propanoic acid). Moreover, the 
organic ligands alone demonstrated significant toxicity in 
vitro, towards a panel of different mice and human cancer 
cell lines [14–16]. O,O’-diethyl-(S,S)-ethylenediamine-
N,N’-di-2-(3-cyclohexyl)propanoate dihydrochloride 
was synthesized as one of novel ester derivates of (S,S)-
ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoic 
acid [14–16]. Among different organic ligands, O,O’-
diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)
propanoate dihydrochloride exhibited considerably similar 
or higher cytotoxic activity than cisplatin [14–16].
However, possible in vivo anticancer effects 
of new synthesized organic ester O,O’-diethyl-(S,S)-
ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate 
dihydrochloride (compound marked as DE-EDCP), has 
not been reported. The aim of our study was to investigate 
the effect of DE-EDCP on 4T1 murine breast cancer 
growth and progression, as well as possible molecular 
mechanism(s) of action.
RESULTS
DE-EDCP exerts cytotoxic capacity against 
mammary carcinoma cells
The effects of DE-EDCP on viability of several 
breast cancer cells (murine 4T1 and human MDA-MB-231 
and MDA-MB-468) were examined using MTT assay. 
Cell viability was tested after treatment with growing 
concentrations of DE-EDCP for 24 and 48 hours, and IC50 
values were calculated. The obtained data showed that 
DE-EDCP decreased viability of all tested tumor cell lines 
in a dose-dependent manner (Figure 1).
Cytotoxic potential of DE-EDCP toward MDA-
MB-468 cells was significantly lower compared to 
cisplatin in concentrations 15.63-31.25 μM after 24 hours 
of exposure and in concentrations 3.90-31.25 μM after 48 
hours treatment (Figure 1A). Cytotoxicity of DE-EDCP 
toward MDA-MB-231 was higher after 24 hours treatment 
in comparison with 48 hours exposure (Figure 1B). Further, 
viability of MDA-MB-231 cells was significantly reduced 
after 24 hours treatment with DE-EDCP in comparison 
with the same treatment with cisplatin (Figure 1B). 
Cytotoxicity of DE-EDCP against MDA-MB-231 cells after 
48 hours exposure was higher than activity of cisplatin for 
concentrations 31.25-500 μM (Figure 1B).
As shown in Figure 1C, at concentrations of 
31.25 μM or higher, DE-EDCP exerted the effective 
dose-dependent cytotoxic effect against 4T1 cells. The 
treatment of 4T1 cells with tested substances for 24 hours 
resulted in approximately equal cytotoxic capacity of DE-
EDCP and referent cytostatic cisplatin in concentrations 
62.5-1000 μM, and more importantly in the lowest 
concentrations 0.49-3.90 μM (Figure 1C). The cytotoxicity 
of tested compound after 48 hours treatment was lower in 
comparison with the effect of cisplatin in concentration 
range from 7.81 to 15.63 μM (Figure 1C).
The IC50 values of DE-EDCP against 4T1 and 
MDA-MB-468 are similar to those for cisplatin, while IC50 
of DE-EDCP against MDA-MB-231 is several times lower 
following 24 hours treatment (Table 1).
The LDH assay confirmed the significant cytotoxic 
effect of DE-EDCP against 4T1 cells (Figure 1D). 
The results revealed that the level of LDH release was 
increased after exposure of 4T1 cells to DE-EDCP for 24 
hours compared to cells treated with cisplatin, indicating 
that DE-EDCP could affect the cell membrane integrity. 
Additionally, DE-EDCP increased the release of LDH 
in a dose-dependent manner. The LDH levels increased 
from 15.67% to 52.02% following DE-EDCP treatment 
in comparison with 10.73% to 26.89% after cisplatin 
treatment at concentration range from 62.5 to 1000 μM.
DE-EDCP reduces tumor growth and metastasis
In view of the pronounced tumoricidal effects of 
DE-EDCP in vitro, the next goal of present study was to 
examine the ability of tested compound to inhibit murine 
breast cancer growth and progression in vivo. 4T1 cells 
were orthotopically implanted into the mammary fat pad 
of mice. After the appearance of palpable tumor, mice 
were treated with DE-EDCP, cisplatin or vehicle.
The short-course treatment with DE-EDCP (10 mg/
kg body weight/5 doses per cycle/2 cycles during 12 days), 
started from the day 5 after tumor cell implantation, was 
associated with the significant reduction of breast cancer 
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growth compared with vehicle treated animals (Figure 
2A). Until day 22, DE-EDCP exhibited similar effects 
on tumor growth as cisplatin. After that point, although 
application of cisplatin showed better effects, tumor growth 
in DE-EDCP treated mice was significantly slower to the 
end of experiment (day 36 following inoculation of tumor 
cells) compared to vehicle treated animals (Figure 2A). 
Furthermore, tumor volume and weight, measured after 
necropsy, were markedly lower in mice treated with DE-
EDCP in comparison to vehicle treated mice (Figure 2A).
On day 36, the pulmonary metastases were detected 
in all injected animals, but the number of metastatic 
colonies was significantly decreased by 1.6-fold in DE-
EDCP treated and 1.7-fold in cisplatin treated mice when 
compared to control animals (Figure 2B). Furthermore, 
DE-EDCP as well as cisplatin effectively reduced the 
size of metastases (4.8-fold and 10.55-fold, respectively) 
(Figure 2C and 2D). Metastatic colonies were not detected 
in the liver of mice treated with DE-EDCP or cisplatin, 
whereas three out of seven vehicle treated mice (42.1%) 
developed liver metastases (Figure 2D).
Tumor cells treated with DE-EDCP undergo 
apoptotic cell death
This experimental study indicates that DE-EDCP 
exhibits beneficial anticancer capacity in 4T1 murine breast 
cancer model. Therefore, the following aim was to identify 
and characterize the mechanisms implicated in DE-EDCP- 
induced inhibition of breast cancer progression.
Table 1: The IC50 values of DE-EDCP and cisplatin determined by MTT assay
Compound IC50 ± SD (μM)
MDA-MB-468 MDA-MB-231 4T1
24 hours 48 hours 24 hours 48 hours 24 hours 48 hours
Cisplatin 16.68±1.83 5.01±1.03 66.01±0.69 20.71±0.32 10.59±0.36 7.97±0.56
DE-EDCP 16.52±2.78 15.58±2.94 5.14±0.63 17.45±3.33 12.90±0.75 12.03±2.86
Data are presented as mean values ± SD from three experiments.
Figure 1: Dose-dependent cytotoxicity of DE-EDCP against human and murine breast cancer cells. (A, B) Effect of DE-
EDCP on viability of MDA-MB-468 and MDA-MB-231 cells after 24h and 48h analyzed with the MTT assay. (C) The viability of 4T1 
cells treated with DE-EDCP and cisplatin for 24h and 48h was evaluated using MTT assay. (D) LDH assay of 4T1 cells treated with DE-
EDCP and cisplatin for 24h. All data are presented as mean values ± SD from three independent experiments performed in triplicates. * p < 
0.05 DE-EDCP vs. cisplatin treated cells.
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Twenty four hours after the treatment with DE-
EDCP at growing concentrations, it was evident that 
4T1 cells became rounded and detached (Figure 3A), 
suggesting that the cancer cells underwent apoptosis. 
Likewise, the treatment with cisplatin induced similar cell 
changes (data not shown). Expression of key apoptosis-
related molecules, Bcl-2, Bax and cleaved caspase-3 
in 4T1 cells following treatment with DE-EDCP or 
cisplatin was visualized by immunofluorescence staining. 
Moderately lower expression of anti-apoptotic Bcl-2 
was observed in cells treated with DE-EDCP compared 
to untreated cells (Figure 3B), while cisplatin clearly 
downregulates the expression of Bcl-2. In contrast, 
expression of both pro-apoptotic Bax and cleaved 
caspase-3 was increased after DE-EDCP or cisplatin 
treatment, compared to untreated 4T1 cells. Quantitative 
analysis of Bcl-2, Bax and caspase-3 mRNA levels is in 
accordance with immunofluorescence staining analysis. 
Bax mRNA levels were significantly increased in DE-
EDCP and cisplatin treated compared to untreated 4T1 
cells (Figure 3C). In addition, DE-EDCP, but not cisplatin, 
increased the expression of caspase-3 mRNA level 
compared to untreated cells (Figure 3C). The caspase-3 
mRNA level was significantly higher in DE-EDCP 
compared to cisplatin treated cells (Figure 3C). Bcl-2 
mRNA level was significantly reduced after DE-EDCP 
and cisplatin treatment (Figure 3C). The lowest Bcl-2 
mRNA level was observed in cisplatin treated cells.
To quantify the apoptotic death of 4T1 cells induced 
by DE-EDCP, Annexin V (AnnV) /Propidium iodide (PI) 
double staining was performed. Growing cell cultures 
were exposed to DE-EDCP or cisplatin at concentrations 
of 31.25 and 62.5 μM for 24 hours. As illustrated in 
Figure 4A and 4B, the majority of apoptotic cells were 
phenotyped as AnnV+/PI+ indicating late apoptosis. 
The obtained data showed that both DE-EDCP and 
cisplatin induced significantly increased late apoptotic 
cell death in comparison to untreated cells, while the 
highest percentage of early apoptotic cells was noticed 
following cisplatin treatment (Figure 4B). Further, at 
lower concentration (31.25 μM), cisplatin induced late 
apoptosis more efficiently than DE-EDCP. However, the 
highest percentage of late apoptotic cells was observed 
after DE-EDCP treatment at the concentration of 62.5 μM 
(Figure 4B). The percentage of late apoptotic cells treated 
with 62.5 μM of DE-EDCP was markedly increased 
Figure 2: DE-EDCP treatment of mice bearing breast cancer inhibits tumor growth and progression. (A) Tumor diameter, 
volume and weight in mice treated with DE-EDCP, cisplatin or phosphate-buffered saline (vehicle) (n=7-8 animals per group) (36th day 
of experiment:* tumor diameter-: DE-EDCP vs. vehicle p=0.005; DE-EDCP vs. cisplatin p=0.001; cisplatin vs. vehicle p=0.000; tumor 
volume-: DE-EDCP vs. vehicle p=0.03; DE-EDCP vs. cisplatin p=0.005; cisplatin vs. vehicle p=0.002; tumor weight-: DE-EDCP vs. 
vehicle p=0.004; DE-EDCP vs. cisplatin p=0.001; cisplatin vs. vehicle p=0.002). (B, C) Number and size of lung metastasis from treated 
mice. Data are presented as mean ± SE (* number of lung metastasis-: DE-EDCP vs. vehicle p=0.032; cisplatin vs. vehicle p=0.008; size 
of lung metastasis-: DE-EDCP vs. vehicle p=0.009; DE-EDCP vs. cisplatin p=0.029; cisplatin vs. vehicle p=0.002). (D) Representative 
hematoxylin and eosin staining of lung and liver tissue sections showing metastatic colonies (arrows) (magnification at x100 and x400).
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Figure 3: Morphological changes and expression of key apoptosis-related molecules in 4T1 cells after DE-EDCP 
treatment. (A) Morphological changes of 4T1 cells exposed to various concentrations of DE-EDCP for 24h. (B) Immunofluorescence 
staining for Bcl-2 (green), Bax (green) and cleaved caspase-3 (green) together with DNA staining with DAPI (blue) in 4T1 cells incubated 
with DE-EDCP or cisplatin (31.25 μM) for 24h, as well as in untreated cells (magnification at x200). (C) mRNA expression of Bcl-2, Bax 
and caspase-3 quantified by RT-PCR in 4T1 cells after DE-EDCP 24h treatment. DE-EDCP treatment markedly increased the expression 
of Bax and caspase-3 mRNA and decreased the expression of Bcl-2 mRNA in 4T1 cells. β-actin mRNA was used as an internal control. 
Data points are represented by the expression ratio and mean±SD fold of control in 4T1 cells. (* Bcl-2-: DE-EDCP vs. untreated p=0.03; 
DE-EDCP vs. cisplatin p=0.006; cislatin vs. untreated p=0.001; Bax-: DE-EDCP vs. untreated p=0.011; cislatin vs. untreated p=0.009; 
caspase-3-: DE-EDCP vs. untreated p=0.015; DE-EDCP vs. cisplatin p=0.021)
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(54.63% ±7.19) in comparison to cisplatin treated cells 
(33.23±2.30) (Figure 4B).
In order to test consistency of proapoptotic 
effect of DE-EDCP ex vivo, we used TUNEL (terminal 
deoxynucleotidyl transferase-mediated dUTP labeling) 
assay for in situ detection of apoptosis-triggered DNA 
fragmentation in tumor tissue. As shown in Figure 4C and 
4D, DE-EDCP and cisplatin treated tumors have more 
TUNEL-positive cells than vehicle treated tumors.
DE-EDCP inhibits proliferation of breast cancer 
cells
We next investigated whether, beside apoptosis, DE-
EDCP inhibits cancer cell proliferation. Consequently, 
the cell cycle profile of 4T1 cells was determined after 
exposure to DE-EDCP or cisplatin for 12 hours. DE-EDCP 
(31.25 μM and 62.5 μM) or cisplatin (31.25 μM) treatment 
significantly increased the percentage of cells in G0/G1 
phase in comparison with untreated cells (Figure 5A). 
Furthermore, the percentage of cells in S and G2/M phases 
was decreased after DE-EDCP and cisplatin treatment 
(Figure 5A). In addition, the significant increase in the 
percentage of cells in sub-G1 phase was found after the 
exposure to DE-EDCP (31.25 μM and 62.5 μM) (Figure 
5A). Overall, the obtained data indicated that DE-EDCP 
inhibited cell proliferation through arrest of cell cycle 
progression in the G0/G1 phase and subsequent induction 
of apoptosis in 4T1 cells. DE-EDCP was more effective at 
higher concentration (62.5 μM), while cisplatin achieved 
similar effect at a concentration as low as 31.25 μM.
Further, we examined the expression of cell-cycle 
progression regulators by flow cytometry. DE-EDCP 
(31.25 μM) or cisplatin (31.25 μM) treatment did not 
affect the expression of cyclin E (Figure 5B). However, 
DE-EDCP treatment significantly reduced cyclin D3 
expression (2.4%±0.37) compared to cisplatin treated 
(3.64%±0.56) and untreated cells (4.64%±1.59) (Figure 
5C and 5E). In line with this finding, marked decrease 
of cyclin D3 mRNA level was observed after DE-EDCP 
treatment compared to untreated cells (Figure 5C).
Both DE-EDCP and cisplatin, enhanced the 
expression of inhibitor of cyclin D-CDK4 complex, p16, 
compared to untreated 4T1 cells (Figure 5D and 5E), thus 
contributing to cell cycle arrest at G0/G1 phase. Also, DE-
EDCP and cisplatin markedly upregulated the expression 
of kinase inhibitor protein (KIP) family members, p21 and 
p27, compared to untreated 4T1 cells (Figure 5D and 5E). 
Figure 4: DE-EDCP enhances tumor cell apoptosis in murine breast cancer. (A) Representative dot plots illustrate population 
of viable (AnnV- PI-), early apoptotic (Ann V+ PI-), late apoptotic (AnnV+ PI+) and necrotic (AnnV- PI+) cells. (B) Apoptosis of untreated 
as well as DE-EDCP and cisplatin (31.25 and 62.5 μМ) treated 4T1 cells were analyzed by flow cytometry using Annexin V (FITC) 
and PI double staining. The data are presented as means ± SD of a three independent experiment, p<0.05 significantly different from: 
*untreated vs. DE-EDCP or cisplatin treated cells; ¶ DE-EDCP vs. cisplatin treated cells; § cisplatin vs. untreated or DE-EDCP treated 
cells. (C) Quantitative analysis of the rate of apoptosis: TUNEL-positive nuclei (brown) were counted in five random fields, and the data 
were summarized as the mean percentage of positive cells. Data are presented as mean ± SD from four tumors per group, (* DE-EDCP vs. 
untreated p=0.028; cisplatin vs. untreated p=0.048). (D) TUNEL assay in breast cancer tissues at 36th day (magnification at x400).
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Figure 5: DE-EDCP induces cell cycle arrest at the G0/G1 checkpoint in 4T1 cells. (A) 4T1 cells cycle analyzed by flow 
cytometry. Results are expressed as the percentage of cells in different phases of the cell cycle. Data are presented as the mean ± SD, p<0.05 
significantly different from: *untreated vs. DE-EDCP or cisplatin treated cells; ¶ DE-EDCP vs. cisplatin treated cells; § DE-EDCP treated 
cells lower and upper concentration. (B) Analysis of cyclin E expression in 4T1 cells exposed to DE-EDCP or cisplatin (31.25 μM) for 
24h using flow cytometry by first gaiting out cell debris and cell clumps in forward/side scatter plot. Data are presented as mean ± SD. (C) 
Analysis of cyclin D3 expression in 4T1 cells exposed to DE-EDCP or cisplatin (31.25 μM) for 24h using flow cytometry by first gaiting 
out cell debris and cell clumps in forward/side scatter plot. Data are presented as mean ± SD (* DE-EDCP vs. untreated p=0.002; DE-EDCP 
vs. cisplatin p=0.01). mRNA expression of cyclin D3 quantified by RT-PCR in 4T1 cells after DE-EDCP (31.25 μM) treatment. β-actin 
mRNA was used as an internal control. Data points are represented by the expression ratio and mean±SD fold of control in 4T1 cells (* DE-
EDCP vs. untreated p=0.017). (D) Analysis of p16, p21 and p27 expression in 4T1 cells exposed to DE-EDCP or cisplatin (31.25 μM) for 
24h using flow cytometry by first gaiting out cell debris and cell clumps in forward/side scatter plot. Data are presented as the mean ± SD 
(* p16-: DE-EDCP vs. untreated p=0.041; cisplatin vs. untreated p=0.034; p21-: DE-EDCP vs. untreated p=0.002; DE-EDCP vs. cisplatin 
p=0.017; cisplatin vs. untreated p=0.001; p27-: DE-EDCP vs. untreated p=0.031; DE-EDCP vs. cisplatin p=0.006; cisplatin vs. untreated 
p=0.004). (E) Representative histograms after flow cytometric analysis of cyclin D3, p16, p21 and p27 of three independent experiments 
are shown.
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The expression of p21 and p27 was increased in cisplatin 
compared to DE-EDCP treated cells. These results suggested 
that the downregulation of cyclin D3 and the upregulation of 
p16, p21 and p27 by DE-EDCP led to cell cycle arrest at G0/
G1 phase, and consequently resulted in growth cell inhibition.
DE-EDCP decreases expression of Ki-67 and 
STAT3
A recent study revealed that Ki-67 and STAT3 
might be promising therapeutic targets in cancer, 
including breast cancer [17, 18]. As evaluated by flow 
cytometry, percentage of Ki-67-positive 4T1 cells treated 
with DE-EDCP (31.25 μM) was significantly decreased 
(24.97%±2.42) compared to untreated (33.43%±5.28) 
and cisplatin treated cells (55.77%±2.70) (Figure 6A). 
Also, there was significant increase of Ki-67 positive 
cells treated with cisplatin compared with untreated 
cells (Figure 6A). Further, immunohistochemistry 
showed decreased percentage of Ki-67-positive cells 
(24.46%±2.45) within breast cancer tissue of DE-EDCP 
treated mice compared to vehicle and cisplatin treated 
animals (36.05%±2.94 and 36.66%±3.47, respectively) 
(Figure 6B and 6C). There was no difference in the 
expression of Ki-67 in breast cancer tissue from mice 
treated with cisplatin or vehicle controls.
DE-EDCP decreased expression of STAT3 
(18.0%±3.05) in 4T1 cells in comparison to cisplatin 
treated (41.23%±12.18) and untreated cells (42.4%±18.62) 
(Figure 7A). In line with this finding, the marked decrease 
of STAT3 mRNA level was observed in 4T1 cells treated 
with DE-EDCP (Figure 7B). Reduction in STAT3 
expression after DE-EDCP treatment was accompanied 
with significantly lower expression of NANOG and SOX2 
mRNA, as one of downstream targets of STAT3 signaling 
pathway (Figure 7B). However, the percentage of Y705 
phospho-STAT3-positive cells within breast cancer tissue 
of DE-EDCP and cisplatin treated mice was decreased 
compared to control group, although this difference did 
not reach statistical significance (Figure 7C and 7D).
DE-EDCP at its effective concentration was well 
tolerated in vivo
Finally, in order to examine the safety of DE-EDCP 
in vivo, the mice’s body weight was assessed before and 
Figure 6: DE-EDCP treatment attenuates expression of Ki-67 in murine breast cancer. (A) Analysis of Ki-67 expression 
in 4T1 cells exposed to DE-EDCP or cisplatin (31.25 μM) for 24h using flow cytometry by first gaiting out cell debris and cell clumps in 
forward/side scatter plot. Data are presented as the mean ± SD, (* DE-EDCP vs. untreated p=0.020; DE-EDCP vs. cisplatin p=0.002; cisplatin 
vs. untreated p=0.009). Representative histograms of three independent experiments are shown. (B, C) At 36th day of the experiment, 
tumors were harvested from tumor-bearing mice treated with DE-EDCP, cisplatin and vehicle and Ki-67 expression was detected using 
immunohistochemical method. Representative images and quantitative analysis of the percentage of Ki-67- positive cells are shown. Ki-
67-positive cells were counted in five random fields (magnification at x 400), and data were summarized as the mean percentage of positive 
cells (four tumors per group). Data are presented as mean ± SE. (*DE-EDCP vs. untreated p=0.006; DE-EDCP vs. cisplatin p=0.004)
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36th day after tumor cell inoculation. Also, on 36th day after 
tumor cell inoculation the serum levels of transaminases 
(AST and ALT), creatinine and urea were measured.
As shown in Figure 8A, DE-EDCP administration 
resulted in significant weight loss at the end of treatment. 
However, DE-EDCP induced reduction of body weight 
was lower in comparison with cisplatin treatment. Mice 
treated with cisplatin lost approximately 22% vs. 10% 
of weight induced by DE-EDCP 36th day after tumor 
cell inoculation (Figure 8A). Further, serum levels of 
creatinine and urea of both naive and tumor-bearing 
mice treated with cisplatin were significantly increased 
compared to DE-EDCP treated or untreated mice 
(Figure 8B). It appears that DE-EDCP did not significantly 
affected systemic levels of creatinine and urea.
There were no significant differences in levels of 
transaminases (data not shown). Additionally, histological 
changes were not observed in organs of mice treated with 
DE-EDCP, including the liver, kidney, lung, intestine, spleen 
and stomach (data not shown). Taken together, obtained 
Figure 7: DE-EDCP treatment downregulates expression of STAT3 in murine breast cancer. (A) Analysis of STAT3 
expression in 4T1 cells exposed to DE-EDCP or cisplatin (31.25 μM) for 24h using flow cytometry by first gaiting out cell debris and 
cell clumps in forward/side scatter plot. Data are presented as the mean ± SD (* DE-EDCP vs. untreated p=0.002; DE-EDCP vs. cisplatin 
p=0.002). Representative histograms of three independent experiments are shown. (B) mRNA expression of STAT3, NANOG and SOX2 
quantified by RT-PCR in 4T1 cells after DE-EDCP (31.25 μM) 24h treatment. β-actin mRNA was used as an internal control. Data points 
are represented by the expression ratio and mean±SD fold of control in 4T1 cells. (* STAT3-: DE-EDCP vs. untreated p=0.008; DE-EDCP 
vs. cisplatin p=0.023; NANOG-: DE-EDCP vs. untreated p=0.019; DE-EDCP vs. cisplatin p=0.029; cisplatin vs. untreated p=0.001; SOX2-
: DE-EDCP vs. untreated p=0.021;. cisplatin vs. untreated p=0.021). (C, D) At 36th day of the experiment, tumors were harvested from 
tumor-bearing mice treated with DE-EDCP, cisplatin and vehicle and phospho-STAT3 expression was detected using immunohistochemical 
method. Representative images and quantitative analysis of the percentage of phospho-STAT3-positive cells are shown. Phospho-STAT3-
positive cells were counted in five random fields (magnification at x 400), and data were summarized as the mean percentage of positive 
cells (four tumors per group). Data are presented as mean ± SE.
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data indicate that DE-EDCP administration is accompanied 
with fewer side effects when compared to cisplatin.
DISCUSSION
The major limitations in cancer treatment are 
drug resistance and severe side effects of conventional 
chemotherapeutics. Due to limitations related to the 
treatment of cancer, there is an opening field for the 
development of novel therapeutic compounds exhibiting 
higher efficiency as well as lower toxicity. Herein, 
anticancer activities of newly synthetized compound 
DE-EDCP were investigated using murine breast cancer 
model. Testing cytotoxicity of organic ligands and their 
corresponding platinum complexes revealed that DE-
EDCP affected the viability of several cancer cell lines 
similarly or even efficiently then cisplatin [14–16]. In fact, 
DE-EDCP exhibited higher cytotoxic capacity compared 
to cisplatin, especially against human acute myelogenous 
(KG-1) and promyelocytic leukemia (HL-60) as well as 
murine melanoma (B16) cell lines [14–16]. These data 
implicate that DE-EDCP might be considered as a valuable 
candidate for anticancer therapy. However, to date the 
effects of DE-EDCP on tumor growth and metastasis are 
unexplored.
DE-EDCP exhibited significant dose-dependent 
cytotoxic effect against murine (4T1) and human (MDA-
MB-468 and MDA-MB-231) breast cancer cell lines 
(Figure 1). The most important finding to emerge from 
present study is that DE-EDCP is capable of favorably 
influencing the course of malignant disease even after 
“therapeutic” administration to mice that have already 
developed tumor. DE-EDCP exhibited marked anticancer 
activity by reducing breast cancer growth and progression 
as evaluated by significantly lower tumor volume and 
weight (Figure 2A) as well as decreased number and 
size of lung and liver metastases when compared to 
untreated group (Figure 2B, 2C and 2D). Also, it should 
Figure 8: Administration of DE-EDCP is accompanied by fewer side effects compared to cisplatin. (A) Body weight of 
tumor-bearing mice treated with DE-EDCP, cisplatin or vehicle before and 36th day of experiment (* DE-EDCP day 36 vs. vehicle day 36 
p=0.023; DE-EDCP day 36 vs. cisplatin day 36 p=0.039; cisplatin day 36 vs. vehicle day 36 p=0.002; cisplatin day 0 vs. cisplatin day 36 
p=0.03). (B) Levels of serum urea and creatinine among cisplatin, DE-EDCP and vehicle treated naive and tumor-bearing mice (n=12-14 
animals per group). Data are presented as mean ± SD. (*creatinine levels-: naive control group cisplatin vs. vehicle p=0.030; cisplatin vs. 
DE-EDCP p=0.029; tumor-bearing group cisplatin vs. vehicle p=0.030; cisplatin vs. DE-EDCP p=0.029; *urea levels-: naive control group 
cisplatin vs. vehicle p=0.005; cisplatin vs. DE-EDCP p=0.005; tumor-bearing group cisplatin vs. DE-EDCP p=0.005).
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be noted that until the 22th day of experiment, DE-EDCP 
exhibited similar effects on tumor growth as cisplatin 
(Figure 2A). After that point, cisplatin showed better 
effects which could be attributed to possible differences 
in pharmacokinetic factors. It is known that cisplatin, as 
metal-based anticancer drug, has low platinum excretion 
rate and is retained in the body, thus achieving its effects 
in a longer period of time, especially when nephrotoxicity 
occurs [4]. However, pharmacokinetic properties of DE-
EDCP remain unknown. Therefore, it seems quite arbitrary 
to assume that application of DE-EDCP, according 
to its organic chemical structure, should not conduct 
to progressive cellular accumulation thus potentially 
avoiding side-effects. As opposed, cellular accumulation 
of cisplatin, especially the relatively high degree of 
accumulation in the renal tissue, might lead to diverse 
side-effects such as cisplatin-induced nephrotoxicity.
It is well known that dysregulations of apoptosis 
and cell proliferation are key events in cancer 
development. Compounds that promote apoptosis and 
inhibit dysfunctional cell proliferation efficiently prevent 
the cancer growth and progression. As a conventional 
chemotherapeutic, cisplatin may trigger the activation 
of both intrinsic and extrinsic pathway of apoptosis 
[4]. Therefore, the next aim of the present study was 
to investigate the possible mechanisms underlying the 
cytotoxic capacity of DE-EDCP. Initially, it was observed 
that 4T1 cells exposed to various concentrations of DE-
EDCP for 24 hours undergo significant morphological 
changes indicating that cell death might occurs via 
apoptosis (Figure 3A). In addition, the expression of 
important counterparts in apoptotic cell death such as anti-
apoptotic Bcl-2, pro-apoptotic Bax or cleaved caspase-3 
[19] was observed in both DE-EDCP- and cisplatin-
treated 4T1 cells as evaluated by immunofluorescence 
(Figure 3B). In line with these findings, treatment with 
DE-EDCP or cisplatin downregulate mRNA level of Bcl-
2 expression and upregulate of Bax and caspase-3 mRNA 
(Figure 3C). Further, DE-EDCP (31.25 and 62.5 μM) 
significantly increased the percentage of late apoptotic 
Ann V+PI+ 4T1 cells in dose-dependent manner following 
24 hours treatment (Figure 4B). The highest percentage 
of late apoptotic cells was observed after DE-EDCP 
treatment at the concentration of 62.5 μM compared to 
untreated, but also to cisplatin treated cells. In addition, 
significantly elevated percentage of TUNEL-positive 
nuclei in breast cancer tissue following exposure to DE-
EDCP or cisplatin (Figure 4C and 4D). In accordance with 
these findings, it was recently established that DE-EDCP 
(50 μM) enhanced the superoxide anion production and 
inner mitochondrial membrane depolarization as evaluated 
by detection of phosphatidylserine externalization and 
DNA fragmentation due to apoptosis of HL-60 cells 
[16]. Pt(II) complex containing DE-EDCP induced HL-
60 oxidative stress and apoptosis further evidenced by 
activation of initiator caspases (caspase-8 and caspase-9) 
[15]. On the other hand, Pt(IV) complex containing DE-
EDCP causes oxidative stress-mediated necrotic death of 
glioma, melanoma and fibrosarcoma cells in vitro [14]. It 
appears that DE-EDCP and corresponding platinum(II) or 
platinum(IV) complexes may trigger at least two different 
types of cancer cell death. However, the authors do not 
exclude the possibility that these difference could be 
due to some specific properties of investigated cell lines. 
Herein, the results obtained from LDH assay strongly 
implicate that DE-EDCP, as opposed to cisplatin, affects 
tumor cell membrane integrity as an alternative way for 
the induction of cell death. Overall, the presented data 
strongly implicate cytotoxic activity of DE-EDCP in vitro 
and ex vivo.
There are evidences that some anticancer agents 
affect cancer cell proliferation by arresting their cell 
cycle in G0/G1 phase [20, 21]. Initially, it was noticed 
that DE-EDCP alters cell cycle status by arresting the 
4T1 cells in G0/G1 phase thus preventing cell cycle 
progression (Figure 5A). Although cyclin E is essential 
for progression through the G1-phase of the cell cycle 
[22], DE-EDCP treatment did not affect the percentage 
of cyclin E-positive 4T1 cells (Figure 5B). Cyclin D3, as 
initial activator of G1/S phase, is one of the critical players 
that drives cell proliferation [23, 24]. Overexpression of 
cyclin D3 has been reported in invasive breast cancer and 
represents an independent prognostic marker [25]. It has 
been demonstrated that the beneficial anticancer effect 
of rapamycin is mainly based on the arresting cells in 
G1 phase due to destabilization and subsequent down-
regulation of cyclin D3 protein in HER2-overexpressing 
breast cancer cells [26]. Accordingly, down-regulation 
of cyclin D3 at both the protein and mRNA levels in 
4T1 cells was noticed following treatment with DE-
EDCP when compared to untreated cells (Figure 5C). 
Besides cyclins, cyclin-dependent kinases and cyclin 
dependent kinases inhibitors tightly regulate the cell cycle 
progression. DE-EDCP caused significant upregulation of 
CIP/KIP (p21 and p27) and INK (p16) cyclin-dependent 
kinase inhibitor levels (Figure 5D). p16 specifically binds 
CDK4 or CDK6 and inhibits cyclin D association in early 
stage of G1 phase [27]. p21 is a universal cyclin-CDK 
inhibitor [28], while p27 prevents the activation of cyclin 
A-Cdk2, cyclin E-CDK2 and cyclin D-CDK4 complexes 
[27, 29]. The results indicate that DE-EDCP induced G1 
cell cycle arrest through downregulating the expression 
of cyclin D3 and upregulating the expression of p16, p21 
and p27.
Ki-67, as widely used marker of cell proliferation, is 
tightly linked to the cell cycle machinery but its exact role 
is still unknown. This nuclear protein is expressed in all 
active phases of cell cycle, but not in quiescent or resting 
cells in the G0 and early G1 phase [30, 31]. For this 
reason, Ki-67 could be used as prognostic biomarker and 
metastatic predictor in many type of human malignancies 
[32–34]. However, recent study reports that Ki-67 is 
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responsible for cancer resistance to chemotherapeutic 
agents via maintaining the cancer stem cell niche [17], 
and suggests that Ki-67 is an attractive therapeutic target 
in cancer. Our data showed that the percentage of Ki67-
positive 4T1 cells exposed to DE-EDCP was markedly 
decreased compared to untreated and cells exposed to 
cisplatin (Figure 6A). Decreased expression of Ki-67 in 
DE-EDCP treated 4T1 cells could be the result of G0/G1 
cell cycle arrest and increased expression of CDK4/CDK6 
inhibitor, p16, as it was previously shown in normal and 
cancer cells [35]. Unexpectedly, the highest percentage of 
Ki-67-positive cells was observed after cisplatin treatment 
(Figure 6A). Further, immunohistochemistry confirms 
that DE-EDCP reduced Ki-67 expression in breast cancer 
ex vivo, but there was no difference in the expression of 
Ki-67 in breast cancer from mice treated with cisplatin 
or vehicle. We speculate that the higher percentage of 
Ki-67-positive cells following cisplatin treatment in vitro 
is mainly related to apoptosis-induced compensatory 
proliferation [36]. This is in line with the results presented 
above which demonstrated that cisplatin was more 
effective inducer of 4T1 cell apoptosis at concentration as 
low as 31.25 μM.
Signal transducer and activator of transcription 3 
(STAT3) is constitutively activated in numerous cancers 
and contributes to different processes involved in tumor 
progression such as cell proliferation, angiogenesis and 
metastasis [18, 37]. Therefore, STAT3 could be considered 
as an important target for cancer treatment. In addition, 
lower activity of STAT3 lead to G0/G1 cell cycle arrest and 
apoptosis [38]. The present study revealed that DE-EDCP 
significantly reduces the percentage of STAT3-positive 
4T1 cells in comparison with untreated or cisplatin treated 
cells (Figure 7A). Also, downregulation of STAT3 mRNA 
in breast cancer cells was noticed following treatment 
with DE-EDCP when compared to both untreated and 
cisplatin exposed cells (Figure 7B). It has been reported 
that knockdown of STAT3 protein in 4T1 cell line by small 
interfering RNA (siRNA) reduce expression of c-Myc and 
completely block expresion of Twist protein, thus inhibiting 
tumor growth and metastasis [39]. Accordingly, it seems 
that one of important anticancer effects of DE-EDCP is the 
reduction of STAT-3 expression in cancer cells.
Recent results reported by Wang H et al [40] 
suggested that SOX2 and NANOG are the key 
downstream proteins of STAT3 signaling pathways in 
cancer. SOX2 and NANOG are transcription factors and 
biomarkers for cancer stem cells (CSCs) [41, 42]. Also, 
evidence has revealed that the SOX2 and NANOG are 
critical factors in conferring certain CSC properties to 
cancer cells such as self-renewal, metastasis and drug 
resistance [43, 44]. Aberrant expression of NANOG has 
been previously found in a variety of tumors, including 
breast cancer [45]. The upregulation of NANOG 
expression is linked to tumor progression and relapse 
[44, 45]. High SOX2 expression was related to adverse 
breast carcinoma profile, less differentiated subtype and 
poor disease outcome [46]. Our data showed that DE-
EDCP treatment significantly reduces NANOG and 
SOX2 mRNA level in 4T1 treated cells compared to 
untreated cells (Figure 7B). Decreased gene expression 
of stemness transcription factors accompanied with lower 
expression of Ki-67 in DE-EDCP treated 4T1 cells is in 
agreement with previous report [17]. In addition, in line 
with finding that DE-EDCP treatment markedly reduced 
expression of STAT3 at protein and mRNA level in vitro, 
immunohistochemistry analysis showed a similar trend for 
decreased percentage of Y705 phospho-STAT3-positive 
cells within breast cancer tissue of DE-EDCP treated mice 
compared to control group, although this difference did 
Figure 9: Chemical structure of O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate dihydrochloride.
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not reach statistical significance (Figure 7C and 7D). A 
previous report demonstrated that knockdown of STAT3 
protein in cervical carcinoma cell line by siRNA reduced 
mRNA and protein expressions of NANOG and SOX2 
[40]. Accordingly, data obtained from our study indicated 
that reduction in STAT3 expression after DE-EDCP 
treatment resulted in significantly lower expression of 
NANOG and SOX2 mRNA.
The main problems with approved anticancer drugs 
today are drug-resistance and lack of selectivity responsible 
for numerous toxic side effects. It is well known that cisplatin 
treatment is associated with nephrotoxicity, hepatotoxicity 
and cardiotoxicity, as well as loss in body weight [4]. Results 
obtained from our study demonstrated that DE-EDCP, in 
effective concentration of 10 mg/kg, was well tolerated in 
vivo. DE-EDCP induced reduction of body weight was lower 
in comparison with cisplatin treatment (Figure 8A). We have 
also observed higher serum levels of both creatinine and urea 
of cisplatin treated mice in comparison to DE-EDCP treated 
mice. Although this side effect of cisplatin is well known, the 
molecular mechanisms underlying cisplatin nephrotoxicity 
is still under investigation [47–49]. On the contrary, DE-
EDCP did not increase serum levels of both creatinine and 
urea compared to untreated animals (Figure 8B). This lack of 
nephrotoxicity may be the consequence of DE-EDCP chemical 
structure as an organic ester. Taken together, obtained data 
indicate that DE-EDCP administration is accompanied with 
fewer side effects when compared to cisplatin.
Collectively, DE-EDCP administration exhibits 
respectable anti-cancer activity with fewer side-effects 
in comparison with conventional chemotherapeutic. It 
appears that tumoricidal capacities of DE-EDCP may be 
achieved by several mechanisms such as triggering cancer 
cell death via apoptosis or nonapoptotic cell death induced 
by direct interfering with cancer cell membrane, and 
inhibition of cell proliferation. The tumoricidal and anti-
proliferative capacities of DE-EDCP might be of interest 





(compound marked as DE-EDCP, Figure 9), was synthesized 
according to previously described procedure [14, 15] and 
registered as patent in Intellectual Property Office of the 
Republic of Serbia (Number 2015/11427-P-2013/0270). 
Cisplatin (cis-diamminedichloroplatinum(II)/cis-[PtCl2(NH3)2]) 
(Sigma-Aldrich) was used without purification.
Cell culture
4T1 mouse mammary carcinoma cell line was 
purchased from American Type Culture Collection 
(CRL-2539TM; ATCC, USA). These cells were 
routinely grown in suspension in complete DMEM 
medium in a 5% CO2 incubator with standard 
conditions. In all in vitro and in vivo experiments only 
cell suspensions with >95% viable cells were used. 




4T1, MDA-MB-231 and MDA-MB-468 cells 
were seeded on 96-well plates at a density of 3 x 103 
cells/100 μl (per well) in complete DMEM (Invitrogen) 
growth medium and were allowed to adhere by 
incubation at 37°C overnight. After 24 hours, culture 
medium were replaced and each well received 100μl 
of different compounds, which had been serially 
diluted two-fold in medium to concentrations ranging 
from 1000 to 0.49 μM. Cells were incubated under 
standard conditions (37°C/5% CO2) for 24 and 48 
hours. Upon incubation medium was removed, MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) solution (5mg/ml in PBS, 20 μl) was added 
to each well and the 96-multiplates were incubated 
for additional 4 hours. Using microplate multimode 
detector Zenyth 3100 the optical density of each well 
was determined at 595 nm. The percentage of cell 
viability was determined by comparison with untreated 
controls according to formula: % of viable cells = (E-
B)/(S-B) x 100 where B is for background of medium 
alone, S is for total viability/spontaneous death of 
untreated target cells, and E is for experimental well 
[50]. Experiments, performed in triplicates, were 
repeated three times.
LDH assay
Cytotoxicity of test compound was examined by 
In Vitro Toxicology Assay Kit (Lactic Dehydrogenase 
based) (Sigma-Aldrich, St. Louis, MO). Cells were 
prepared and treated with test compound in the same 
way as for MTT assay. A high control, leading to 
100% cytotoxicity by lysing the cells completely, was 
included in the assay. Cells exposed to medium only 
were used as a low control. After 24 hours of treatment, 
supernatant (50 μl) was transferred to new multiplate and 
incubated with previously prepared substrate solution 
(100 μl). Plates were protected from light and incubated 
at room temperature for 30 minutes. The reaction 
was stopped by stop solution and data were acquired 
by spectrophotometry at 490 nm. Experiments were 
repeated three times. The percentage of dead cells was 
calculated using the formula [51]:
% dead cells = (exp. value-low control)/(high 
control-low control) x 100
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Annexin V propidium iodide double staining 
assay
Annexin V is cellular protein with ability to bind 
to phosphatidylserine when it is on the external portion 
of the plasma membrane. Propidium iodide (PI), as small 
fluorescent molecule, binds to DNA but cannot passively 
traverse into cells if plasma membrane remains intact 
[52]. After 24 hours of treatment with test compound 
at concentrations 31.25 and 62.5 μM, 4T1 cells were 
stained with Annexin V-FITC, followed addition of PI 
(BD Pharmingen, San Diego, California, USA) according 
to the manufacturer’s instructions. The percentages 
of dead cells were determined by FACS Calibur flow 
cytometer (BD Biosciences, San Jose, USA) and the data 
were analyzed using FlowJo (Tree Star). It is considered 
that Annexin V- PI- are viable cells, Annexin V+PI- are 
cells in early stage of apoptosis, Annexin V+ PI+ are 
cells in late stage of apoptosis, while Annexin V- PI+ are 
necrotic cells.
Cell cycle analysis
4T1 cells were allowed to grow until 70–80% 
confluent in culture plates and were exposed to DE-EDCP 
or cisplatin (31.25 and 62.5 μM) for 12 hours and cell 
cycle analysis was performed with Vybrant® DyeCycle™ 
Ruby stain (Thermo Fisher Scientific, Inc. USA) according 
to manufacturer’s instructions. After treatment, 4T1 cells 
were stained with Vybrant DyeCycle Ruby and analyzed 
by FACS Calibur flow Cytometer (BD Biosciences, San 
Jose, USA). The cell cycle distribution was analyzed using 
FlowJo software [53].
Flow cytometric analysis
4T1 cells, grown in culture plates, were treated 
with either DE-EDCP or cisplatin (31.25 μM) for 
24 hours. Next, the treated cells were fixed and 
permeabilized with permeabilization buffer (BD 
Bioscience) and incubated with antibodies specific 
for STAT3 (IC1799G, Novus Biologicals, San Diego, 
USA), Ki-67 (11-5698-82, eBioscience, San Diego, 
USA), cyclin D3 (ab28283, Abcam Cambridge, United 
Kingdom), cyclin E (MA5-14336, Thermo fisher 
scientifics, USA), p16 (ab211542, Abcam Cambridge, 
United Kingdom), p21 (ab188224, Abcam Cambridge, 
United Kingdom) and p27 (ab215434, Abcam 
Cambridge, United Kingdom). For staining cyclin D3, 
cyclin E, p16, p21 and p27 cells were additionally 
incubated with secondary goat anti-mouse IgG FITC 
(ab6785 Abcam Cambridge, United Kingdom) or 
donkey anti-rabbit IgG (ab150073 Abcam Cambridge, 
United Kingdom). Flow cytometry was conducted on 
FACSCalibur flow cytometer (BD Biosciences, San 
Jose, USA) and the data were analyzed using FlowJo 
(Tree Star).
Immunofluorescencent staining
The expression of Bcl-2, Bax and cleaved caspase-3 
proteins were investigated by immunofluorescence 
method as previously described [54]. In brief, the 4T1 
cells were seeded in a 6-well plate and exposed to the 
DE-EDCP and cisplatin at concentration of 31.25 μM for 
24 hours. After washing the cells twice with PBS, they 
were fixed in 4% paraformaldehyde at 25°C for 20 min. 
The cells were stained with rabbit polyclonal antibody 
specific for Bcl-2 (sc-783, Santa Cruz Biotech. Inc CA, 
USA), Bax (sc-493, Santa Cruz Biotech. Inc CA, USA) 
and active/cleaved caspase-3 (NB100-56113, Novus 
Biologicals, UK). After incubation, the cells were washed 
and treated with appropriate secondary antibody, goat 
anti-rabbit IgG FITC (Ab6717-1, Abcam, Cambridge, 
United Kingdom). The sections were mounted with 
ProLong Gold antifade reagent with DAPI (Invitrogen) 
and analyzed at x 200 magnification using fluorescent 
microscope (Olympus BX 51).
Real-time PCR analysis
4T1 cells were treated with DE-EDCP and 
cisplatin (31.25 μM) for 24 hours. Total RNA from 4T1 
cell was isolated with TRIzol (Invitrogen, Carlsbad, 
CA). First-strand cDNA was synthesized by High 
Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, California, USA). qRT-PCR 
was performed using Power SYBR MasterMix (Applied 
Biosystems) and mRNA specific primers for Bax 
(forward 5´-ACACCTGAGCTGACCTTG-3´ and reverse 
5´-AGCCCATGATGGTTCTGATC-3´), Bcl-2 (forward 
5´-GTGGTGGAGGAACTCTTCAG -3´ and reverse 
5´-GTTCCACAAAGGCATCCCAG-3´), Caspase-3 
(forward 5´-AAATTCAAGGGACGGGTCAT-3´ and reverse 
5´-ATTGACACAATACACGGGATCTGT-3´), STAT3 
(forward 5´-GGCATTCGGGAAGTATTGTCG-3´ and 
reverse 5´- GGTAGGCGCCTCAGTCGTATC-3´), Cyclin 
D3 (forward 5´- CCGTGATTGCGCACGACTTC-3´ and 
reverse 5´-TCTGTGGGAGTGCTGGTCTG-3´), NANOG 
(forward 5´-AAGCAGAAGATGCGGACTGT-3´ and 
reverse 5´-GTGCTGAGCCCTTCTGAATC-3´), SOX2 
(forward 5´-AAAGGGTTCTTGCTGGGTTT-3´ and 
reverse 5´-AGACCACGAAAACGGTCTTG-3´) and β-actin 
(forward 5´-AGCTGCGTTTTACACCCTTT-3´ and reverse 
5´-AAGCCATGCCAATGTTGTCT -3´) as a housekeeping 
gene. qRT-PCR reactions were initiated with a 10 minute 
incubation time at 95°C followed by 40 cycles of 95°C for 
15 seconds and 60°C for 60 seconds in a Mastercycler ep 
realplex (Eppendorf, Hamburg, Germany). For each sample 
(four per group) relative amount of mRNA was normalized 
to the β-actin content. Fold expression changes relative to 
4T1 cells were calculated with the ΔΔCT method [55]. Data 
points are represented by the expression ratio and mean±SD 
fold of control in 4T1 cells.
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Experimental animals
All experiments were approved by and conducted 
in accordance with the Guidelines of the Animal Ethics 
Committee of the Faculty of Medical Sciences of the 
University of Kragujevac, Serbia. Female (8–10 weeks 
old) BALB/c mice were used. The mice were housed in 
a temperature-controlled environment with a 12-hour 
light-dark cycle, fed ad libitum and observed daily. Also, 
experimental animals were equalized in weight and 
randomized in experimental or control groups.
Animal model and drug treatment
Orthotopic breast cancer model
BALB/c mice were inoculated with 3 x 104 4T1 cells 
orthotopically into the fourth mammary fat pad. Five days 
after 4T1 cells were applied, the mice were injected with 
a chemotherapy drug by intraperitoneal injection. Female 
BALB/c mice received either DE-EDCP (10 mg/kg body 
weight/ for 5 consecutive days followed by 2 days break 
and treated again for 5 days), cisplatin (3mg /kg/dose; 
three times per week; nine doses in total) or phosphate-
buffered saline. Mice were sacrificed on 36th day of the 
experiment.
Estimation of breast cancer growth
The size of primary 4T1 mammary tumors was 
assessed morphometrically using electronic calipers in two 
dimensions. Using a below formula the tumor volumes 
(mm3) were calculated [56]: tumor volume (mm3)=L 
(major axis of the tumor) x W(minor axis)2/2.
Histopathological analysis of metastatic lung and 
liver
Hematoxylin-eosin (H&E) staining was performed 
using 4 μm paraffin-embedded tumor bearing lung or 
liver sections. In order to avoid missing micrometastases, 
stained sections from at least three different levels were 
examined for the presence of lung or liver metastases. 
Metastases were verified at magnification x 100 and x 400 
and photomicrographed with a digital camera mounted on 
light microscope (Olympus BX51). In the histological 
section metastatic area per tissue was calculated using 
ImageJ software [57].
In situ TUNEL staining
The TUNEL (terminal deoxynucleotidyl transferase 
mediated dUTP nickend labeling) reaction was performed to 
assess apoptotic cells within breast cancer tissues sections. 
Formalin-fixed, paraffin-embedded tissue sections were 
stained with Apo-tag TUNEL assay kit (Millipore, Temecula, 
CA, USA) following the protocol of manufacturer. DAB 
(3,3’-diaminobenzidine) as peroxidase substrate, was used 
to yield the characteristic brown color for nuclei. Following 
rinsing, slides were counterstained with hematoxylin solution 
and photomicrographed with a digital camera mounted on 
light microscope. The negative control was performed by 
omitting TdT reaction step. The TUNEL-positive nuclei 
(brown) were quantified under × 400 magnification in five 
randomly fields representing at least 1000 neoplastic nuclei 
and the data were summarized as the mean percentage of 
positive cells (four tumors per group) [58].
Immunohistochemical detection of Ki-67 and 
phospho-STAT3 (pSTAT3) in breast cancer 
tissues
Briefly, paraffin-embedded breast cancer tissue 
sections were deparaffinized, rehydrated and subjected 
to heat-induced antigen retrieval in citrate buffer (pH 
6.0). Next, sections were incubated with rabbit anti-
mouse Ki-67 antibody (ab66155, Abcam, Cambridge, 
United Kingdom) or STAT3 (phospho Y705) antibody 
(ab76315, Abcam, Cambridge, United Kingdom) followed 
by visualization using the rabbit-specific conjugate 
(Expose Rb-Specific HRP/AEC Detection IHC Kit; 
Abcam Cambridge, United Kingdom). The slides were 
photomicrographed with a digital camera mounted on light 
microscope. The negative control slides were obtained by 
omitting the primary antibody.
The Ki-67-positive, as well as pSTAT3-positive, cells 
were determined by counting at least 1000 neoplastic nuclei 
per slide in five randomly selected fields (at magnification 
x 400). The data were summarized as the mean percentage 
of positive cells (four tumors per group) [59].
Toxicity assessment
To study the potential side effects in the DE-EDCP 
treated mice, they were remarked for weight loss. After 
sacrificed, tissue sections of various organs (liver, kidney, 
lung, intestine, spleen and stomach) stained with H&E and 
were also examined. The levels of serum urea, creatinine 
and transaminase were determined to assess the renal and 
hepatic function. After blood collection, serum levels of 
these toxicity markers were measured immediately using 
assay kits and blood chemistry analyzer, as described [60].
Statistical analysis
The data were analyzed using software package 
IBM SPSS Statistics version 20. First the normality of 
data distribution was tested by Kolmogorov-Smirnov 
or Shapirov-Will test. The two-tailed Student’s t test 
or nonparametric Mann–Whitney Rank Sum test were 
used. All data in this study were expressed as the mean ± 
standard deviation (SD) or standard error (SE). Values of p 
< 0.05 were considered as statistically significant.
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